Merck launches accelerator programme for AI startups
pharmaphorum
JUNE 30, 2022
The exploratory research phase for DSP-1181 was less than a year, compared to the average of five years using traditional drug design processes, according to the two developers. However, most novel active compounds identified with the help of AI are still in discovery or preclinical stages of development.
Let's personalize your content